Osteocalcin as a marker of metabolic risk in healthy postmenopausal women

García-Martín, Antonia; Cortés-Berdonces, María; Luque-Fernandez, Ines; Rozas-Moreno, Pedro; Quesada-Charneco, Miguel; Muñóz-Torres, Manuel

doi:10.1097/gme.0b013e3181f8565e

Cited by 40 publications

(23 citation statements)

References 18 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 In another study, the authors found that osteocalcin was associated with BMI, WC, FBG, and systolic blood pressure and played a key role in the pathogenesis of metabolic syndrome. 24 Consistent with these findings, we also observed significantly lower osteocalcin levels in metabolic syndrome patients.…”

Section: Discussionsupporting

confidence: 89%

Relationships Among the Metabolic Syndrome, Bone Mineral Density, Bone Turnover Markers, and Hyperglycemia

Terzi¹,

Dindar²,

Terzi³

et al. 2015

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

After adjusting for age and BMI in a comparison of BMD between postmenopausal women with and without metabolic syndrome, it was revealed that metabolic syndrome has no positive or negative effect on BMD. In contrast, a negative correlation was identified between FBG and HbA1c levels and lumbar BMD, suggesting that poor glycemic control may have a negative effect on lumbar BMD in this group of patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Relationships Among the Metabolic Syndrome, Bone Mineral Density, Bone Turnover Markers, and Hyperglycemia

Terzi¹,

Dindar²,

Terzi³

et al. 2015

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

show abstract

“…These studies found that osteocalcin was negatively correlated with fasting plasma glucose, insulin, and glycohemoglobin A1c [17]. Beyond negative correlations with glucose metabolism, some studies also report negative correlations between osteocalcin and broader parameters like body mass index, insulin resistance, adipokine levels, and fat mass, suggesting a link with metabolic syndrome [18][19][20][21][22][23][24][25][26][27]. Our data provide direct support for the notion that in humans, uncarboxylated osteocalcin regulates blood glucose and energy metabolism.…”

Section: Discussionsupporting

confidence: 71%

Osteoid osteoma is an osteocalcinoma affecting glucose metabolism

et al. 2011

View full text Add to dashboard Cite

Osteocalcin is a hormone secreted by osteoblasts, which regulates energy metabolism by increasing β-cell proliferation, insulin secretion, insulin sensitivity, and energy expenditure. This has been demonstrated in mice, but to date, the evidence implicating osteocalcin in the regulation of energy metabolism in humans are indirect. To address this question more directly, we asked whether a benign osteoblastic tumor, such as osteoma osteoid in young adults, may secrete osteocalcin. The study was designed to assess the effect of surgical resection of osteoid osteoma on osteocalcin and blood glucose levels in comparison with patients undergoing knee surgery and healthy volunteers. Blood collections were performed the day of surgery and the following morning after overnight fasting. Patients and controls were recruited in the orthopedic surgery department of New York Presbiterian Hospital, NY-USA and Hospices Civils de Lyon, France. Seven young males were included in the study: two had osteoid osteoma, two underwent knee surgery, and three were healthy volunteers. After resection of the osteoid osteomas, we observed a decrease of osteocalcin by 62% and 30% from the initial levels. Simultaneously, blood glucose increased respectively by 32% and 15%. Bone turnover markers were not affected. This case study shows for the first time that osteocalcin in humans affects blood glucose level. This study also suggests that ostoid osteoma may be considered, at least in part, as an osteocalcinoma.

show abstract

“…In contrast to our results, another study in postmenopausal women (mean age 56 years, BMI 29 [25]), detected an inverse association of circulating serum osteocalcin with FPG, but the number of cases was too low to make such a conclusion (8 patients with FPG ≥100 mg/dl vs. 46 FPG <100 mg/dl). The authors only measured FPG in their study and none of the insulin resistance parameters were evaluated.…”

Section: Discussioncontrasting

confidence: 55%

“…Garcia-Martin et al [25] found significantly lower osteocalcin levels in a group with BMI ≥30 compared with cases with BMI <30 (14.4 ± 8.8 vs. 17.3 ± 6.2 ng/ml, p = 0.034). In our study, we also detected a significant difference in BMI groups.…”

Section: Discussionmentioning

confidence: 99%

The Association of Osteocalcin and Adiponectin with Glucose Metabolism in Nondiabetic Postmenopausal Women

Çağlar¹,

Özdemir²,

Kiseli³

et al. 2014

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aim: This study was designed to determine if osteocalcin is associated with insulin resistance, metabolic risk factors and adiponectin levels in nondiabetic postmenopausal women. Methods: A total of 87 menopausal nondiabetic subjects were enrolled into the study. Levels of fasting plasma glucose (FPG), insulin and serum lipids were determined. To estimate insulin sensitivity, homeostasis model assessment (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI) were used. Serum total osteocalcin and adiponectin levels were measured and the features of metabolic syndrome were identified. Results: The mean age of the patients was 54.7 years. Among the participants, 28.7% were obese (body mass index, BMI, ≥30). Insulin resistance was detected by HOMA-IR in 42.5% and by the QUICKI index in 63.2% of the cases. Metabolic syndrome was present in 29.8% of the patients. Neither the baseline characteristics nor the metabolic risk factors were correlated with osteocalcin or adiponectin levels (p > 0.05). When the patients were analyzed regarding BMI, osteocalcin levels were significantly lower in overweight women. Serum adiponectin levels were significantly lower in women with metabolic syndrome. Conclusion: No correlation between total osteocalcin and FPG, fasting insulin and insulin resistance parameters was found in nondiabetic postmenopausal women. Serum levels of adiponectin were associated with metabolic syndrome.

show abstract

Osteocalcin as a marker of metabolic risk in healthy postmenopausal women

Abstract: In this population, there is a consistent association between osteocalcin and markers of metabolic syndrome. We suggest potential usefulness of serum osteocalcin as a predictor for increased risk of diabetes in postmenopausal women.

Cited by 40 publications

References 18 publications

Relationships Among the Metabolic Syndrome, Bone Mineral Density, Bone Turnover Markers, and Hyperglycemia

Relationships Among the Metabolic Syndrome, Bone Mineral Density, Bone Turnover Markers, and Hyperglycemia

Osteoid osteoma is an osteocalcinoma affecting glucose metabolism

The Association of Osteocalcin and Adiponectin with Glucose Metabolism in Nondiabetic Postmenopausal Women

Contact Info

Product

Resources

About